Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix provided its Q3 2024 update, highlighting key operational progress. The company transferred US sponsorship of the global Phase 3 NANORAY-312 head and neck cancer study to Janssen, marking a important step toward potential NBTXR3 regulatory submission. The company reported €53.2 million in cash and cash equivalents as of September 30, 2024, with runway into Q4 2025.

Updates on NBTXR3 in pancreatic cancer and lung cancer studies with MD Anderson are expected in Q4 2024 and 1H 2025, respectively. The company strengthened its Supervisory Board with Dr. Margaret A. Liu and Ms. Anat Naschitz as board observers. An interim analysis for NANORAY-312 is anticipated after reaching required events and last patient recruitment in 1H 2026.

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announces participation in three major healthcare conferences in November 2024. The company will engage in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 11, Boston), the Stifel Healthcare Conference (Nov 18, New York), and the Jefferies London Healthcare Conference (Nov 20, London). Company executives Laurent Levy (CEO) and Bart van Rhijn (CFO) will present at these events. All sessions will be webcast live and available for replay on the company's investor relations website.

Nanobiotix (NBTX), a company listed on Euronext Paris and Nasdaq, has released its monthly report on voting rights and share capital as of September 30, 2024. This disclosure is in compliance with French regulatory requirements. The company reported 47,426,851 shares outstanding, with 49,200,752 total theoretical voting rights and 49,178,634 total exercisable voting rights.

Nanobiotix, traded under the ticker NANO:FP on Bloomberg and NANO.PA on Reuters, is committed to regular updates on its capital structure. The company will publish new figures monthly if there are changes from previously disclosed information, adhering to transparency standards set by French financial authorities.

Nanobiotix (NASDAQ: NBTX) provided a business update and reported half-year 2024 financial results. Key highlights include:

1. Favorable safety profile and tumor response for RT-NBTXR3 followed by anti-PD-1 in head and neck cancer patients.

2. Several clinical milestones expected in the next 12-18 months for pancreatic, head and neck, esophageal, and lung cancers.

3. €66.3 million in cash and cash equivalents as of June 30, 2024, with runway extended into Q4 2025.

4. Revenue increased to €9.3 million, up from €3.3 million in H1 2023.

5. Net loss of €21.9 million, or €0.46 per share, compared to €28.1 million, or €0.80 per share in H1 2023.

6. Ongoing global Phase 3 trial (NANORAY-312) for head and neck cancer with interim analysis expected by 1H2026.

Nanobiotix (Euronext: NANO – NASDAQ: NBTX) has nominated Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board. Dr. Liu, CEO of PAX Therapeutics, is a global expert in vaccines, gene therapy, and cancer immunotherapy. Ms. Naschitz, co-founder of OrbiMed Israel, is a proven life science investor and entrepreneur.

These additions aim to equip Nanobiotix for sustainable long-term growth. Dr. Liu brings experience in academia, pharmaceuticals, biotechnology, and public policy. Ms. Naschitz offers expertise in capital utilization for disruptive innovation. Both nominees have extensive global experience in the biopharmaceutical industry, which is expected to reinforce Nanobiotix's strategic initiatives in oncology for NBTXR3 and expand development opportunities beyond it.

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will feature a fireside chat with company management on Wednesday, September 11, 2024, at 9:30 AM EDT / 3:30 PM CEST in New York, NY.

Presenters include Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer. The fireside chat will be webcast live from the company's website, with a replay available after the event. Nanobiotix is known for pioneering physics-based approaches to expand treatment possibilities for cancer patients.

Nanobiotix, a company listed on Euronext Paris and Nasdaq, has released its monthly report on voting rights and shares capital as of July 31, 2024. The report, in compliance with French regulatory requirements, reveals the following key figures:

• Number of Shares Outstanding: 47,426,851
• Total Theoretical Voting Rights: 49,200,912
• Total Exercisable Voting Rights: 49,178,794

This disclosure is part of Nanobiotix's commitment to transparency and adherence to French financial regulations. The company trades under the ticker NBTX on Nasdaq and is part of Euronext Paris Compartment B.

Nanobiotix has disclosed its voting rights and share capital details as of June 30, 2024. The company has 47,426,851 shares outstanding and 49,198,624 total voting rights, with 49,176,506 voting rights exercisable. This disclosure aligns with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority. Nanobiotix will continue to publish monthly updates if there are changes in the voting rights and shares comprising its capital.

NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, when combined with immunotherapy, has shown promising results in controlling disease and tumor response in head and neck cancer patients. Detailed insights from the 2024 ASCO Annual Meeting will be reviewed, highlighting NBTXR3's mechanisms, patient treatment responses, and its potential role in addressing unmet medical needs in recurrent or metastatic head and neck cancer. Registration for the event is available online, and it will be replayed and archived on the company's website.